Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 23, 2013 - Issue 2
Submit an article Journal homepage
248
Views
16
CrossRef citations to date
0
Altmetric
Reviews

Falcipain inhibitors as potential therapeutics for resistant strains of malaria: a patent review

Uttam Rajaram ManeThe M. S. University of Baroda, Pharmacy Department, Faculty of Tech. and Engg, Vadodara, 390001, Gujarat, India+91 265 2434187; +91 265 2418927; [email protected];Torrent Research Centre, Village Bhat, Dist. Gandhinagar, 382421, Gujarat, India
,
Ramesh C GuptaTorrent Research Centre, Village Bhat, Dist. Gandhinagar, 382421, Gujarat, India
,
Sunil Sadanand NadkarniTorrent Research Centre, Village Bhat, Dist. Gandhinagar, 382421, Gujarat, India
,
Rajani R GiridharThe M. S. University of Baroda, Pharmacy Department, Faculty of Tech. and Engg, Vadodara, 390001, Gujarat, India+91 265 2434187; +91 265 2418927; [email protected]
,
Prashant Prakash NaikThe M. S. University of Baroda, Pharmacy Department, Faculty of Tech. and Engg, Vadodara, 390001, Gujarat, India+91 265 2434187; +91 265 2418927; [email protected]
&
Mange R YadavThe M. S. University of Baroda, Pharmacy Department, Faculty of Tech. and Engg, Vadodara, 390001, Gujarat, India+91 265 2434187; +91 265 2418927; [email protected]
Pages 165-187 | Published online: 11 Dec 2012

Bibliography

  • WHO reports 2010. 2011. Available from: http://www.rollbackmalaria.org
  • Snow RW, Guerra CA, Noor AM, The global distribution of clinical episodes of P. falciparum malaria. Nature 2005;434:214-17
  • Fidock DA, Rosenthal PJ, Croft SL, Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004;3:509-20
  • Rosenthal PJ. Proteases of malaria parasites: new targets for chemotherapy. Emerg Infect Dis 1998;4(1):49-57
  • Medicine for Malaria Venture. Available from: http://www.mmv.org
  • Nwaka S, Riopel L, Ubben D, Craft JC. Medicines for Malaria Venture new developments in antimalarials. Travel Med Infect Dis 2004;2:161-70
  • Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of P. falciparum. J Biol Chem 2000;275:29000-10
  • Castell DA. Antimalarial agents. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. 5th edition. John Wiley & Sons, Inc; New York: 1997. p. 3-91
  • Rosenthal PJ. Review Antimalarial drug discovery: old and new approaches. J Exp Biol 2003;206:3735-44
  • Korde R, Bhardwaj A, Singh R, A prodomain peptide of P. falciparum cysteine protease (falcipain-2) inhibits malaria parasite development. J Med Chem 2008;51:3116-23
  • Eggleson KK, Duffin KL, Goldberg DE. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite. J Biol Chem 1999;274:32411-17
  • Klemba M, Gluzman I, Goldberg DE. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 2004;279(41):43000-7
  • Hanspal M, Dua M, Takakuwa Y, Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal protein at late stage of parasite development. Blood 2002;100(3):1048-54
  • Shenai BR, Semenov AV, Rosenthal PJ. Stage-specific antimalarial activity of cysteine protease inhibitors. Biol Chem 2002;383:843-7
  • Dhawan S, Dua M, Chishti AH, Hanspal M. Ankyrin peptide blocks falcipain-2-mediated malaria parasite release from red blood cells. J Biol Chem 2003;278(32):30180-6
  • Hogg T, Nagarajan K, Herzberg S, Structural and functional characterization of falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum. J Boil Chem 2006;281:25425-37
  • Rosenthal PJ, Sijwali PS, Singh A, Shenai BR. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr Pharm Des 2002;8:1659-72
  • Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem 2000;275:29000-10
  • Sijwali PS, Shenai BR, Gut J, Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem J 2001;360:481-9
  • Shenai BR, Rosenthal PJ. Reducing requirements for hemoglobin hydrolysis by Plasmodium falciparum cysteine proteases. Mol Biochem Parasitol 2002;122:99-104
  • Sijwali PS, Koo J, Singh N, Rosenthal PJ. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol Biochem Parasitol 2006;150:96-106
  • Rosenthal PJ. Falcipains and other cysteine proteases of malaria parasites. Adv Exp Med Biol 2011;712:30-48
  • Singh N, Sijwali PS, Pandey KC, Rosenthal PJ. Plasmodium falciparum: biochemical characterization of the cysteine protease falcipain-2. Exp Parasitol 2006;112:187-92
  • Sijwali PS, Kato K, Seydel KB, Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc Natl Acad Sci USA 2004;101:8721-6
  • Sijwali PS, Rosenthal PJ. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in haemoglobin hydrolysis by P. falciparum. Proc Natl Acad Sci USA 2004;101:4384-9
  • Coteron JM, Catterick D, Castro J, Falcipain inhibitors: optimization studies of the 2-Pyrimidinecarbonitrile lead series. J Med Chem 2010;53:6129-52
  • Marco M, Coteron JM. Falcipain inhibition as a promising antimalarial target. Curr Top Med Chem 2012;12(5):408-44
  • Ettari R, Bova F, Zappala M, Falcipain-2 inhibitors. Med Res Rev 2010;30(1):136-67
  • Rosenthal PJ, Olson JE, Lee GK, Antimalarial effects of vinyl sulphone cysteine proteinase inhibitors. Antimicrob Agents Chemother 1996;40:1600-3
  • Shenai BR, Lee BJ, Alvarez-Hernandez A, Structure-activity relationships for inhibition of cysteine protease activity and development of P. falciparum by peptidyl vinyl sulfones. Antimicrob Agents Chemother 2003;47(1):154-60
  • Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. Antimalarial effects of peptide inhibitors of a plasmodium falciparum cysteine proteinase. J Clin Invest 1991;88:1467-72
  • Lee BJ, Singh A, Chiang P, Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob Agents Chemother 2003;47(12):3810-14
  • Bhattacharya A, Mishra LC, Sharma M, Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum in vitro. Eur J Med Chem 2009;44:3388-93
  • Zhu J, Chen T, Chen L, 2-Amido-3-(1H-indol-3-yl)-N-substitued-propanamides as a new class of falcipain-2 inhibitors. Molecules 2009;14:494-508
  • Zhu J, Chen T, Liu J, 2-(3,4-Dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio)acetamides as a new class of falcipain-2 inhibitors. Molecules 2009;14:785-97
  • Liu Y, Cui K, Lu W, Synthesis and antimalarial activity of novel dihydro-artemisinin derivatives. Molecules 2011;16:4527-38
  • Micale N, Ettari R, Schirmeister T, Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors. Bioorg Med Chem 2009;17:6505-11
  • Loser R, Gut J, Rosenthal PJ, Antimalarial activity of azadipeptide nitriles. Bioorg Med Chem Lett 2010;20:252-5
  • Ettari R, Zappala M, Micale N, Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. Eur J Med Chem 2010;45:3228-33
  • Hans RH, Gut J, Rosenthal PJ, Chibale K. Comparison of the antiplasmodial and falcipain-2 inhibitory activity of b-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids. Bioorg Med Chem Lett 2010;20:2234-7
  • Capela R, Oliveira R, Goncalves LM, Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg Med Chem Lett 2009;19:3229-32
  • Gibbons P, Verissimo E, Araujo NC, Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity. J Med Chem 2010;53:8202-6
  • Huang H, Lu W, Li X, Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent. Bioorg Med Chem Lett 2012;22:958-62
  • Desai PV, Panty A, Sabnis Y, Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The chembridge database. J Med Chem 2004;47:6609-15
  • Li H, Huang J, Chen L, Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. J Med Chem 2009;52:4936-40
  • Thompson SK, Veber DF, Tomaszek TA, Tew DG. SmithKline Beecham Corp. Treatment of parasitic diseases by inhibition of cysteine proteases inhibition of the papain superfamily. WO99053039; 1999
  • Thompson SK, Veber DF, Tomaszek TA, Tew DG. GlaxoSmithKline. Treatment of parasitic disease by inhibition of cysteine proteases of the papain superfamily. US20020156018; 2002
  • Tew DG, Thompson SK, Veber DF. SmithKline Beecham Corp. Method of treatment. WO200217924; 2002
  • Thompson SK, Tew DG, Veber DF. GlaxoSmithKline. Method of treatment. US20030044399; 2003
  • Cummings MD, Marquis RW, Yu RU. SmithKline Beecham Corp. Protease inhibitors. WO0170232; 2001
  • Cummings MD, Marquis RW, Yu RU, SmithKline Beecham Corp. Protease inhibitors. US20040044201; 2004
  • Cummings MD, Veber DF, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. US7071184; 2006
  • Cummings MD, Marquis RW, Yu RU. SmithKline Beecham Corp. Protease inhibitors. US20060194787; 2006
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. WO03097593; 2003
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. US20050256100; 2005
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. WO03099844; 2003
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. US20050256105; 2005
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. WO03103574; 2003
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. WO03104257; 2003
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. US20050234038; 2005
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. US7109233; 2006
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. WO2005034838; 2005
  • Jeong JU, Yamashita DS. SmithKline Beecham Corp. Protease inhibitors. US20050203084; 2005
  • Clark WM, Badham NF, Dai Q, SmithKline Beecham Corp. Method of preparation of benzofuran-2-carboxylic acid {(S)-3-methyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-ylcarbamoyl]butyl}amide. WO2005069981; 2005
  • Clark WM, Badham NF, Dai Q, SmithKline Beecham Corp. Method of preparation of benzofuran-2-carboxylic acid {(S)-3-methyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-ylcarbamoyl]butyl}amide. US20080262224; 2008
  • Castro P, Chaparro M, Coteron L, Glaxo Group Ltd. 2,4-subtituted pyrimidines as cysteine protease inhibitors. WO2006027211; 2006
  • Castellote A, Coteron L, Fernandez V, Glaxo Group Ltd. Novel cysteine protease inhibitors. WO2007025774; 2007
  • Chaparro M, Coteron L, Fernandez V, Glaxo Group Ltd. Novel cysteine protease inhibitors. WO2007025775; 2007
  • Coteron L, Fernandez V, Fiandor R. Glaxo Group Ltd. Novel cysteine protease inhibitors. WO2007025776; 2007
  • Coteron L, Fiandor R, Kusalakumari S. Glaxo Group Ltd. Novel substituted pyrimidines as cysteine protease inhibitors. WO2008052934; 2008
  • Coteron L, Fiandor R, Kusalakumari S. Glaxo Group Ltd. Novel substituted pyrimidines as cysteine protease inhibitors. US20100009956; 2010
  • Coteron L, Diaz H, Fiandor R, Macro M. Glaxo Group Ltd. Novel purines as cysteine protease inhibitors. WO2008107368; 2008
  • Coteron L, Diaz H, Fiandor R, Macro M. SmithKline Beecham Corp. Purines as cysteine protease inhibitors. US20100105652; 2010
  • Ekstein JW. Enanta Pharmaceuticals, Inc. Bifunctional inhibitors of malarial cysteine protease and uses there of. WO0183433; 2001
  • Lim-Wilby M, Semple JE, Araldi GL, Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections. WO200248097; 2002
  • Quibell M, Taylor S, Grabowska U, Medivir A. B. Cysteine protease inhibitors. WO02040462; 2002
  • Quibell M, Taylor S, Grabowska U, Medivir A. B. Cysteine protease inhibitors. WO020462; 2002
  • Quibell M, Taylor S, Grabowska U, (Birch Steward Kolasch & Birch). Cysteine protease inhibitors. US20030203900; 2003
  • Quibell M, Taylor S, Grabowska U, (Birch Steward Kolasch & Birch). Cysteine protease inhibitors. US20050020588; 2005
  • Quibell M, Taylor S, Grabowska U, (Birch Steward Kolasch & Birch). Cysteine protease inhibitors. US20030186962; 2003
  • Quibell M, Taylor S, Grabowska U, (Birch Steward Kolasch & Birch). Cysteine protease inhibitors. US20040229915; 2004
  • Quibell M, Taylor S, Grabowska U, Medivir. Cysteine protease inhibitors. US20050070598; 2005
  • Cohen FE, Du X, Guo C, Mckerrow JH. The Regents of the University of California. Thiosemicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use. US20040014801; 2004
  • Cohen FE, Du X, Guo C, Mckerrow JH. The Regents of the University of California. Thiosemicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use. US20050182121; 2005
  • Chibale K, Greenbaum DC, Mckerrow JH. The Regents of the University of California. Anti-parasitic compounds and methods of their use. WO2005087211; 2005
  • Chibale K. The Regents of the University of California. Anti-parasitic compounds and methods of their use. US20070197495; 2007
  • Renslo A, Mahajan S. The Regents of the University of California. Prodrug and fluoregenic compositions and methods for using the same. WO20100011684; 2010
  • Hanspal, Manjit, Chishti AH. Cartias St. Elizabeth's Medical Center of Boston, Inc. Compositions and methods for inhibiting malaria protease falcipain-2. WO2004052914; 2004
  • GonzalezA, Rodriguez P, Izquierdo F. Universtat Jaume. Cysteine-protease inhibitors Peptidic epoxides. WO2008152178; 2008
  • GonzalezA, Rodriguez P, Izquierdo F. Universtat Jaume. Cysteine-protease inhibitors Peptidic epoxides. US20100190848; 2010
  • ZhanW, Huang J, Shan L, The Second Military Medical University and East China University of Science and Technology. Use of flavonoid glycoside compounds in manufacturing medicament for the treating malaria. WO2011047529; 2011
  • SingleL, Huang J, Zhang W, The Second Military Medical University and East China University of Science and Technology. Cynanversicoside C in the preparation of glycosides sprawling Baiwei treatment of malaria drugs in the application. Application of cynanversicoside C in preparation of medicines for treating malaria. CN101693036; 2010
  • ZhangW, Huang J, Single L, The Second Military Medical University and East China University of Science and Technology. Flavonoid glycosides in the preparation of the application of drugs to treat malaria. application of flavonoid glycoside compounds in preparation of medicines for treating malaria. CN101693037; 2010
  • Schirmeister T, Schmuck C, Machon U. Julius Maximilians University of Wuerzburg and Technical University Carolo Wilhelmina, Brunscwick. N-Protected guanidine-substituted furans, thiophenes and pyrrols as cysteine protease inhibitors. WO2010037536; 2010
  • Quibell M. Incenta Ltd. Inhibitors of cruzapain and other cysteine proteases. WO02057270; 2002; Listen
  • Quibell M. Amura Therapeutics Ltd. Inhibitors of cruzapain and other cysteine proteases. US20040138250; 2004
  • Quibell M. Amura Therapeutics Ltd. Inhibitors of cruzapain and other cysteine proteases. US7425562; 2008
  • Quibell M. Amura Therapeutics Ltd. Inhibitors of cruzapain and other cysteine proteases. US20090247471; 2009
  • Quibell M Incenta Ltd. Inhibitors of cruzapain and other cysteine proteases. WO02057248; 2002
  • Quibell M Amura Therapeutics Ltd. Inhibitors of cruzapain and other cysteine proteases. US20040127424; 2004
  • Quibell M Amura Therapeutics Ltd. Inhibitors of cruzapain and other cysteine proteases. US7132449; 2006
  • Quibell M Amura Therapeutics Ltd. Cyclic 2-carbonylaminoketones as inhibitors of cruzapain and other cysteine proteases. WO2002057249; 2005
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Preparation of Tetrahydrofuro(3,2-b) pyrrol-3-one derivatives as inhibitors of cysteine proteinases. WO2008007107; 2008
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones as cathepsin K inhibitors. WO2008007112; 2008
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. WO2008007127; 2008
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. US20100010009; 2010
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. WO2008007130; 2008
  • Quibell M, Watts JP, (Edward anglel palmer & dodge LLP). Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. US20090192170; 2009
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol derivatives. WO2008007103; 2008
  • Quibell M, Watts JP, (Edward anglel palmer & dodge LLP). Furo(3,2-b) pyrrol derivatives. US20090186906; 2009
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol derivatives. US20100216811; 2010
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones derivatives as inhibitors of cysteine proteases. WO2009144450; 2009
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol derivatives. US7737150; 2010
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. WO2008007109; 2008
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. US20090203714; 2009
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. US7846935; 2010
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones derivatives and their use as cysteinyl proteinase inhibitors. US7846934; 2010
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones as cathepsin K inhibitors. WO2008007114; 2008
  • Quibell M, Watts JP, (Edward anglel palmer & dodge LLP). Tetrahydrofuro(3,2-b) pyrrol-3-ones as cathepsin K inhibitors. US20090197817; 2009
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones as cathepsin K inhibitors. US7803803; 2010
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones derivatives as inhibitors of cysteine proteinases. US20090186831; 2009
  • Quibell M, Watts JP, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones derivatives as inhibitors of cysteine proteinases. US7799791; 2010
  • Quibell M, Watts JP, Flinn NS, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones as cathepsin S inhibitors. WO2009112826; 2009
  • Quibell M, Watts JP, Flinn NS, Amura Therapeutics Ltd. Furo(3,2-b) pyrrol-3-ones as cathepsin S inhibitors. WO20110009386; 2011
  • Quibell M, Watts JP, Flinn NS, Amura Therapeutics Ltd. Compounds. WO2009112839; 2009
  • Quibell M, Watts JP, Flinn NS, Amura Therapeutics Ltd. Compounds. US20110009385; 2011
  • Quibell M, Nally P, Patien L, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones intermediates. WO2008007132; 2008
  • Quibell M, Nally P, Patien L, Amura Therapeutics Ltd. Tetrahydrofuro(3,2-b) pyrrol-3-ones intermediates. US20090192322; 2009
  • Quibell M, Watts JP, Flinn NS, Amura Therapeutics Ltd. Compounds. WO2009087379; 2009
  • Quibell M, Watts JP, Flinn NS, Amura Therapeutics Ltd. Compounds. US20110077254; 2011
  • Quibell M, Ramjee MK, Incenta Ltd. Inhibitors of cruzapain and other cysteine proteases. WO02057246; 2002
  • Quibell M, Ramjee MK, Amura Therapeutics Ltd. Inhibitors of cruzapain and other cysteine proteases. US6958358; 2005
  • Quibell M, Ray PC, Watts JP, Amura Therapeutics Ltd. Biologically active compounds. WO2004007501; 2004
  • Quibell M, Ray PC, Watts JP, Amura Therapeutics Ltd. Biologically active compounds. US20060100431; 2006
  • Quibell M, Watts JP, Wang Y, Amura Therapeutics Ltd. Biologically active compounds. US20090131502; 2009
  • Quibell M, Watts JP, Wang Y, Amura Therapeutics Ltd. Biologically active compounds. WO2007023281; 2007
  • Quibell M, Wang Y, Nally JP, Amura Therapeutics Ltd. Preparation of diazapentalene derivatives via epoxidation of dihydropyrroles. WO2007017698; 2007
  • Quibell M, Wang Y, Nally JP, Amura Therapeutics Ltd. Preparation of diazapentalene derivatives via epoxidation of dihydropyrroles. US20090005575; 2009
  • Bachovchin WW; (Fish & Neave IP Group Ropes & Gary LLP One International place). Protease inhibitors. US20060089312; 2006
  • Black C, Beaulieu C, Merck frost Canada Ltd. Cathepsin cysteine protease inhibitors for the treatment of various diseases. WO2010148488; 2010
  • Clinical status. Available from: www.thomson-pharma.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.